Apixaban
- Generic Name
- Apixaban
- Brand Names
- Eliquis, Apixaban Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N5O4
- CAS Number
- 503612-47-3
- Unique Ingredient Identifier
- 3Z9Y7UWC1J
- Background
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.
- Indication
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism
- Associated Therapies
- -
Drug Interaction Study of Apixaban With Cyclosporine or Tacrolimus in Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- University of Saskatchewan
- Target Recruit Count
- 14
- Registration Number
- NCT04023760
- Locations
- 🇨🇦
Saskatchewan Health Authority, Saskatoon, Saskatchewan, Canada
Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension
- Conditions
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 166
- Registration Number
- NCT04007289
- Locations
- 🇫🇷
Beaujon hospital, Clichy, France
DOAC Versus VKA After Cardiac Surgery
- Conditions
- Interventions
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Laval University
- Registration Number
- NCT04002011
Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
- Conditions
- Interventions
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Victor Tapson, MD
- Target Recruit Count
- 4
- Registration Number
- NCT03988842
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis
- Conditions
- Interventions
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 151
- Registration Number
- NCT03987711
- Locations
- 🇦🇺
Prince of Wales Hospital, Randwick, New South Wales, Australia
🇦🇺Royal North Shore Hospital, Saint Leonards, New South Wales, Australia
🇨🇦Health Sciences North, Sudbury, Ontario, Canada
MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention
- Conditions
- Interventions
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 620
- Registration Number
- NCT03961334
- Locations
- 🇬🇷
Attikon University Hospital, Athens, Greece
🇪🇸Hospital Universitario Virgen Macarena, Sevilla, Spain
🇨🇭University Hospital of Basel, Basel, Switzerland
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
- Conditions
- Interventions
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Yale University
- Target Recruit Count
- 700
- Registration Number
- NCT03907046
- Locations
- 🇺🇸
St. Jude Medical Center, Fullerton, California, United States
🇺🇸Ascension Sacred Heart Pensacola, Pensacola, Florida, United States
🇺🇸Javon Bea Hospital - Riverside, Rockford, Illinois, United States
Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 34
- Registration Number
- NCT03839355
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Apixaban for Extended Anticoagulation (APIDULCIS)
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Arianna Anticoagulazione Foundation
- Target Recruit Count
- 800
- Registration Number
- NCT03678506
- Locations
- 🇮🇹
Daniela Poli, Firenze, Italy
Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)
- Conditions
- Interventions
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT03594045
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.